Cited by 389Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsInflammatory mediators and NSAID effects

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib

Open access

ADAPT Research Group*·2008·Archives of Neurology

DOI 10.1001/archneur.2008.65.7.nct70006PMC PMC2925195

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Observational studies have shown reduced risk of Alzheimer dementia in users of nonsteroidal anti-inflammatory drugs. OBJECTIVE: To evaluate the effects of naproxen sodium and celecoxib on cognitive function in older adults. DESIGN: Randomized, double-masked chemoprevention trial. SETTING: Six US memory clinics. PARTICIPANTS: Men and women aged 70 years and older with a family history of Alzheimer disease; 2117 of 2528 enrolled had follow-up cognitive assessment. INTERVENTIONS: Celecoxib (200 mg twice daily), naproxen sodium (220 mg twice daily), or placebo, randomly allocated in a ratio of 1:1:1.5, respectively. MAIN OUTCOME MEASURES: Seven tests of cognitive function and a global summary score measured annually. RESULTS: Longitudinal analyses showed lower global summary scores over time for naproxen compared with placebo (- 0.05 SDs; P = .02) and lower scores on the Modified Mini-Mental State Examination over time for both treatment groups compared with placebo (- 0.33 points for celecoxib [P = .04] and - 0.36 points for naproxen [P = .02]). Restriction of analyses to measures collected from persons without dementia attenuated the treatment group differences. Analyses limited to measures obtained while participants were being issued study drugs produced results similar to the intention-to-treat analyses. CONCLUSIONS: Use of naproxen or celecoxib did not improve cognitive function. There was weak evidence for a detrimental effect of naproxen.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/archneur.2008.65.7.nct70006

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L., Hempelman, S. R., Berry, D. A., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 991
Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review
Szekely, C. A., Thorne, J. E., Zandi, P. P., Ek, M., Messias, E., Breitner, J. C. S., & Goodman, S. N. (2004) · Neuroepidemiology · doi:10.1159/000078501 · Cited by 402
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402
A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease
Scharf, S., Mander, A. G., Ugoni, A., Vajda, F. J. E., & Christophidis, N. (1999) · Neurology · doi:10.1212/wnl.53.1.197 · Cited by 385
Rofecoxib
Reines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R., Norman, B., & Baranak, C. C. (2004) · Neurology · doi:10.1212/wnl.62.1.66 · Cited by 384
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354
Self-citation
Reduced incidence of AD with NSAID but not H2receptor antagonists
Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K. M., Mayer, L. S., & Breitner, J. C. S. (2002) · Neurology · doi:10.1212/wnl.59.6.880 · Cited by 317

Show all 20 references

Research works printed but not linked: 2

Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1):66-71.
Sainati S, Ingram D, Talwalker S, Geis G. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzhei- mer's disease. Presented at: The Sixth International Stockholm-Springfield Symposium of Advances in Alzheimer's Therapy; April 5-8, 2000; Stockholm, Sweden.

Sorted by citations

Items 101–200 of 389

The effects of cardiovascular risk factors on cognitive compromise
Beeri, M. S., Ravona‐Springer, R., Silverman, J. M., & Haroutunian, V. H. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/msbeeri · Cited by 101
Exacerbation of CNS inflammation and neurodegeneration by systemic LPS treatment is independent of circulating IL-1β and IL-6
Murray, C., Skelly, D., & Cunningham, C. M. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-50 · Cited by 100
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias
Ihl, R., Frölich, L., Winblad, B. G., Schneider, L. S. S., Burns, A. S., Möller, H., & WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and other Dementias (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.538083 · Cited by 99
Celecoxib or Naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial
Fields, C., Drye, L., Vaidya, V., & Lyketsos, C. (2012) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318227f4da · Cited by 96
Microglia in Alzheimer's Disease: It's All About Context
Weitz, T. M., & Town, T. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/314185 · Cited by 95
“The result of this trial indicated no protection afforded by NSAIDs (naproxen or celecoxib) on cognitive scores, and weak evidence for lower cognitive scores in naproxen users [40, 41].”
Background
Acetaminophen inhibits neuronal inflammation and protects neurons from oxidative stress
Tripathy, D., & Grammas, P. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-10 · Cited by 97
Non-psychiatric comorbidity associated with Alzheimer's disease
Duthie, A. C., Chew, D., & Soiza, R. L. (2011) · QJM · doi:10.1093/qjmed/hcr118 · Cited by 92
Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer’s disease
Taylor, J. M., Moore, Z., Minter, M. R., & Crack, P. J. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1745-4 · Cited by 94
Lipid metabolism and neuroinflammation in Alzheimer’s disease: a role for liver X receptors
Kang, J., & Rivest, S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1049 · Cited by 94
Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease
Shi, J., Wang, Q., Johansson, J. U., Liang, X., Woodling, N. S., Priyam, P. G., Loui, T., Merchant, M. J., BREYER, R. M., Montine, T. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23677 · Cited by 93
Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Hsu, D. C., & Marshall, G. A. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160930112125 · Cited by 95
S3-Leitlinie „Demenzen“
Frölich, L. (2010) · Der Nervenarzt · doi:10.1007/s00115-010-2999-3 · Cited by 93
Inflammation, Cytokines, Immune Response, Apolipoprotein E, Cholesterol, and Oxidative Stress in Alzheimer Disease: Therapeutic Implications
Candore, G., Bulati, M., Caruso, C., Castiglia, L., Colonna‐Romano, G., Bona, D. D., Duro, G., Lio, D., Matranga, D., Pellicanò, M., et al. (2010) · Rejuvenation Research · doi:10.1089/rej.2009.0993 · Cited by 95
CAP—advancing the evaluation of preclinical Alzheimer disease treatments
Reiman, E. M., Langbaum, J. B. S., Tariot, P. N., Lopera, F. J., Bateman, R. J., Morris, J. C., Sperling, R. A., Aisen, P. S. S., Roses, A. D., Welsh-Bohmer, K. A., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.177 · Cited by 92
Therapeutic potential of mGluR5 targeting in Alzheimer's disease
Kumar, A., Dhull, D. K., & Mishra, P. S. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00215 · Cited by 93
Thymus involution sets the clock of the aging T-cell landscape: Implications for declined immunity and tissue repair
Elyahu, Y., & Monsonego, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101231 · Cited by 93
Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's disease
Satlin, A., Wang, J., Logovinsky, V., Berry, S. M., Swanson, C. J., Dhadda, S., & Berry, D. A. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.01.001 · Cited by 89
Targeting microglia for the treatment of Alzheimer’s disease
McGeer, P. L., & McGeer, E. G. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.988707 · Cited by 92
Emerging Therapeutics for Alzheimer's Disease
Chiang, K., & Koo, E. H. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135932 · Cited by 95
Human CNS immune senescence and neurodegeneration
Streit, W. J., & Xue, Q.-S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.05.005 · Cited by 86
Nitric oxide in neurodegeneration: potential benefits of non-steroidal anti-inflammatories
Doherty, G. H. (2011) · Neuroscience Bulletin · doi:10.1007/s12264-011-1530-6 · Cited by 91
Erythrocyte membrane-encapsulated celecoxib improves the cognitive decline of Alzheimer's disease by concurrently inducing neurogenesis and reducing apoptosis in APP/PS1 transgenic mice
Guo, J., Guan, P.-P., Ding, W.-Y., Wang, S., Huang, X., Wang, Z., & Wang, P. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.023 · Cited by 86
Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation
Moore, A. H., Bigbee, M. J., Boynton, G. E., Wakeham, C. M., Rosenheim, H. M., Staral, C. J., Morrissey, J. L., & Hund, A. K. (2010) · Pharmaceuticals · doi:10.3390/ph3061812 · Cited by 90
Vascular Factors and Markers of Inflammation in Offspring With a Parental History of Late-Onset Alzheimer Disease
van Exel, E. R., Eikelenboom, P., Comijs, H. C., Frölich, M., Smit, J. H., Stek, M. L., Scheltens, P., Eefsting, J. E., & Westendorp, R. G. J. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.146 · Cited by 82
Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimers Disease
Cole, G. M., & Frautschy, S. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791011991 · Cited by 85
Follow‐up evaluation of cognitive function in the randomized Alzheimer's Disease Anti‐inflammatory Prevention Trial and its Follow‐up Study
ADAPT-FS Research Group (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.03.009 · Cited by 83
Self-citation
Proliferation in the Alzheimer Hippocampus Is due to Microglia, Not Astroglia, and Occurs at Sites of Amyloid Deposition
Marlatt, M. W., Bauer, J., Aronica, E., van Haastert, E. S., Hoozemans, J. J. M., Joels, M., & Lucassen, P. J. (2014) · Neural Plasticity · doi:10.1155/2014/693851 · Cited by 83
“Neuroinflammation is prominent during AD [8–10] and microglia have consistently been implicated in brain aging, neuroinflammation, and neurodegeneration [11–13].”
Background
Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: Boosting autoimmunity to fight-off chronic neuroinflammation
Schwartz, M., & Baruch, K. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.08.002 · Cited by 85
Harmful Effects of NSAIDs among Patients with Hypertension and Coronary Artery Disease
Bavry, A. A., Khaliq, A., Gong, Y., Handberg, E. M., Cooper‐DeHoff, R. M., & Pepine, C. J. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.02.025 · Cited by 80
Simultaneous activation of Nrf2 and elevation of antioxidant compounds for reducing oxidative stress and chronic inflammation in human Alzheimer's disease
Prasad, K. N. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.01.002 · Cited by 83
Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics
Deardorff, W. J., & Grossberg, G. T. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1200972 · Cited by 85
Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS 1 mouse model
Qiao, J., Wang, J., Wang, H., Zhang, Y., Zhu, S., Adilijiang, A., Guo, H., Zhang, R., Guo, W., Luo, G., et al. (2015) · Glia · doi:10.1002/glia.22926 · Cited by 82
The Role of Microglia in Sporadic Alzheimer’s Disease
Streit, W. J., Khoshbouei, H., & Bechmann, I. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201248 · Cited by 87
Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer’s disease
Singh, A. K., Singh, S. K., Nandi, M. K., Mishra, G., Maurya, A., Rai, A., Rai, G. K., Awasthi, R., Sharma, B., & Kulkarni, G. T. (2019) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524919666190820160053 · Cited by 79
Novel Applications of NSAIDs: Insight and Future Perspectives in Cardiovascular, Neurodegenerative, Diabetes and Cancer Disease Therapy
Kaduševičius, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126637 · Cited by 85
The Alzheimer’s Prevention Initiative Composite Cognitive Test Score
Ayutyanont, N., Langbaum, J. B. S., Hendrix, S. B., Chen, K., Fleisher, A., Friesenhahn, M. J., Ward, M. E., Aguirre, C., Acosta‐Baena, N., Madrigal, L., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08927 · Cited by 84
Microglia in dementia with Lewy bodies
Streit, W. J., & Xue, Q. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.10.012 · Cited by 78
Midlife predictors of Alzheimer's disease
Bendlin, B. B., Carlsson, C. M., Gleason, C. E., Johnson, S. C., Sodhi, A., Gallagher, C. L., Puglielli, L., Engelman, C. D., Ries, M. L., Xu, G., et al. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.12.014 · Cited by 81
Vascular pathology: Cause or effect in Alzheimer disease?
Rius‐Pérez, S., Tormos, A. M., Pérez, S., & Taléns‐Visconti, R. (2017) · Neurología (English Edition) · doi:10.1016/j.nrleng.2015.07.008 · Cited by 79
Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease
Kulshreshtha, A., & Piplani, P. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2625-7 · Cited by 76
Increased Myeloperoxidase Plasma Levels in Patients with Alzheimer's Disease
Tzikas, S., Schlak, D., Sopova, K., Gatsiou, A., Stakos, D., Stamatelopoulos, K. S., Stellos, K., & Laske, C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131469 · Cited by 75
Immune-Inflammatory Responses and Oxidative Stress in Alzheimers Disease: Therapeutic Implications
Bona, D. D., Scapagnini, G., Candore, G., Castiglia, L., Colonna‐Romano, G., Duro, G., Nuzzo, D., Iemolo, F., Lio, D., Pellicanò, M., et al. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790883769 · Cited by 76
Why Did Tarenflurbil Fail in Alzheimer's Disease?
Imbimbo, B. P. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1092 · Cited by 75
Neuroinflammatory challenges compromise neuronal function in the aging brain: Postoperative cognitive delirium and Alzheimer’s disease
Cortese, G. P., & Bürger, C. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.08.027 · Cited by 77
Defining and labeling disease‐modifying treatments for Alzheimer's disease
Cummings, J. L. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.12.003 · Cited by 75
Guideline Watch (October 2014): Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias
Rabins, P. V., Rovner, B. W., Rummans, T. A., Schneider, L. S. S., & Tariot, P. N. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.15106 · Cited by 77
Using genetics to enable studies on the prevention of Alzheimer's disease
Crenshaw, D. G., Gottschalk, W. K., Lutz, M. W., Grossman, I., Saunders, A. M., Burke, J. R., Welsh-Bohmer, K. A., Brannan, S. K., Burns, D. K., & Roses, A. D. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.222 · Cited by 70
Cause-Specific Cardiovascular Risk Associated with Nonsteroidal Anti-Inflammatory Drugs among Myocardial Infarction Patients - A Nationwide Study
Olsen, A. S., Fosbøl, E. L., Lindhardsen, J., Andersson, C., Folke, F., Nielsen, M. R. I., Køber, L., Hansen, P. R., Torp-Pedersen, C. T., & Gislason, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054309 · Cited by 70
Patología vascular: ¿causa o efecto en la enfermedad de Alzheimer?
Rius‐Pérez, S., Tormos, A. M., Pérez, S., & Taléns‐Visconti, R. (2015) · Neurología · doi:10.1016/j.nrl.2015.07.010 · Cited by 74
Inflammation: Bridging Age, Menopause and APOEε4 Genotype to Alzheimer’s Disease
Mishra, A., & Brinton, R. D. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00312 · Cited by 71
Anesthesia, surgery, illness and Alzheimer's disease
Eckenhoff, R. G., & Laudansky, K. F. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.011 · Cited by 68
The role of inflammatory processes in Alzheimer’s disease
Broussard, G. J., Mytar, J. O., Li, R., & Klapstein, G. J. (2012) · Inflammopharmacology · doi:10.1007/s10787-012-0130-z · Cited by 71
Peripherally triggered and GSK-3β-driven brain inflammation differentially skew adult hippocampal neurogenesis, behavioral pattern separation and microglial activation in response to ibuprofen
Llorens-Martín, M., Jurado‐Arjona, J., Fuster-Matanzo, A., Hernández, F., Rábano, A., & Ávila, J. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.92 · Cited by 69
Therapeutic implications of the prostaglandin pathway in Alzheimer's disease
Cudaback, E., Jorstad, N. L., Yang, Y. J., Montine, T. J., & Keene, C. D. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.014 · Cited by 68
Multi-domain interventions for the prevention of dementia and cognitive decline
Hafdi, M., Hoevenaar‐Blom, M. P., & Richard, E. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013572 · Cited by 68
Effects of long‐term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer
Alibhai, S. M. H., Timilshina, N., Duff-Canning, S. J., Breunis, H., Tannock, I. F., Naglie, G., Fleshner, N. E., Krahn, M. D., Warde, P. R., Marzouk, S., et al. (2016) · Cancer · doi:10.1002/cncr.30320 · Cited by 65
The Cache County Study on Memory in Aging: Factors affecting risk of Alzheimer's disease and its progression after onset
Tschanz, J. T., Norton, M. C., Zandi, P. P., & Lyketsos, C. G. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.849663 · Cited by 69
Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE 2 Signaling in Alzheimer’s Disease
Woodling, N. S., & Andreasson, K. I. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00016 · Cited by 62
Modulation of inflammatory pathways by the immune cholinergic system
Nizri‏, E., & Brenner, T. (2011) · Amino Acids · doi:10.1007/s00726-011-1192-8 · Cited by 65
The neuroendocrine control of the innate immune system in health and brain diseases
Bellavance, M., & Rivest, S. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01129.x · Cited by 61
Four Decades of Research in Alzheimer’s Disease (1975–2014): A Bibliometric and Scientometric Analysis
Serrano‐Pozo, A., Aldridge, G. M., & Zhang, Q. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170184 · Cited by 59
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B. P., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G., Lofano, L., Creanza, B. C., et al. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1241232 · Cited by 61
Alzheimers Disease: Pathological Mechanisms and Recent Insights
Niedowicz, D. M., Nelson, P. T., & Murphy, M. P. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376181 · Cited by 62
Cognitive and Cerebral Metabolic Effects of Celecoxib Versus Placebo in People With Age-Related Memory Loss: Randomized Controlled Study
Small, G. W., Siddarth, P., Silverman, D. H. S., Ercoli, L. M., Miller, K. J., Lavretsky, H., Bookheimer, S. Y., Huang, S.-C., Barrio, J. R., & Phelps, M. E. (2008) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31818cd3a4 · Cited by 60
Aggregation of the Inflammatory S100A8 Precedes Aβ Plaque Formation in Transgenic APP Mice: Positive Feedback for S100A8 and Aβ Productions
Lodeiro, M., Puerta, E., Ismail, M.-A.-M., Rodriguez‐Rodriguez, P., Rönnbäck, A., Codita, A., Parrado‐Fernández, C., Maioli, S., Gil-Bea, F. J., Merino‐Serrais, P., et al. (2016) · The Journals of Gerontology Series A · doi:10.1093/gerona/glw073 · Cited by 55
Hippocampal subfield transcriptome analysis in schizophrenia psychosis
Perez, J. M., Berto, S., Gleason, K., Ghose, S., Tan, C., Kim, T.-K., Konopka, G., & Tamminga, C. A. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0696-6 · Cited by 55
Clinical trials for preventing post stroke cognitive impairment
Ankolekar, S., Geeganage, C. M., Anderton, P., Hogg, C., & Bath, P. M. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.08.052 · Cited by 58
Preventing cognitive decline in healthy older adults
Naqvi, R. M., Liberman, D., Rosenberg, J., Alston, J., & Straus, S. E. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.121448 · Cited by 56
Two‐level diagnostic classification using cerebrospinal fluid YKL‐40 in Alzheimer's disease
Baldacci, F., Toschi, N., Lista, S., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S., Cavedo, E., dos Santos, A. M., Epelbaum, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.021 · Cited by 53
Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia
Schlachetzki, J. C. M., Fiebich, B. L., Haake, E., de Oliveira, A. C., Candelario‐Jalil, E., Heneka, M. T., & Hüll, M. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-2 · Cited by 55
Why have we Failed to Cure Alzheimer's Disease?
Korczyn, A. D. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110359 · Cited by 55
Evaluation of Two Potent and Selective PET Radioligands to Image COX-1 and COX-2 in Rhesus Monkeys
Kim, M.-J., Shrestha, S., Cortes, M., Singh, P., Morse, C. L., Liow, J., Gladding, R. L., Brouwer, C., Henry, K. A., Gallagher, E. P., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.211144 · Cited by 52
Non-Steroidal Anti-Inflammatory Drugs and Cognitive Function: Are Prostaglandins at the Heart of Cognitive Impairment in Dementia and Delirium ?
Cunningham, C. M., & Skelly, D. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9312-5 · Cited by 51
Curcumin: a natural substance with potential efficacy in Alzheimer’s disease
Potter, P. E. (2013) · Journal of Experimental Pharmacology · doi:10.2147/jep.s26803 · Cited by 51
Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases
Cornec, A., Monti, L., Kovalevich, J., Makani, V. S., James, M. J., Vijayendran, K. G., Oukoloff, K., Yao, Y., Lee, V. M. ‐., Trojanowski, J. Q., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00475 · Cited by 50
Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease
Kline, A. D. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt135 · Cited by 53
Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors
Herbst, K. J., Liu, L., James, M., Yao, Y., Xie, S. X., & Brunden, K. R. (2015) · Scientific Reports · doi:10.1038/srep18286 · Cited by 50
DOCK2 Is a Microglial Specific Regulator of Central Nervous System Innate Immunity Found in Normal and Alzheimer’s Disease Brain
Cimino, P. J., Sokal, I., Leverenz, J., Fukui, Y., & Montine, T. J. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090443 · Cited by 49
Myeloid Dendritic Cells are Potential Players in Human Neurodegenerative Diseases
Bossù, P., Spalletta, G., Caltagirone, C., & Ciaramella, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00632 · Cited by 51
Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship
Bettcher, B. M., & Kramer, J. H. (2012) · Neurocase · doi:10.1080/13554794.2011.654227 · Cited by 49
A tale of two systems: Lessons learned from female mid-life aging with implications for Alzheimer’s prevention & treatment
Mishra, A., Wang, Y., Yin, F., Vitali, F., Rodgers, K. E., Soto, M., Mosconi, L., Wang, T., & Brinton, R. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101542 · Cited by 48
No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease
Hillmann, A., Hahn, S., Schilling, S., Hoffmann, T., Demuth, H., Bulic, B., Schneider-Axmann, T., Bayer, T. A., Weggen, S., & Wirths, O. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.006 · Cited by 46
Role of Traditional Nonsteroidal Anti-inflammatory Drugs in Alzheimer’s Disease
Gupta, P. P., Pandey, R. D., Jha, D., Shrivastav, V. K., & Kumar, S. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317514542644 · Cited by 46
Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease
Coma, M., Serenó, L., Rocha-Souto, B. D., Scotton, T. C., España, J., Sánchez‐Saudinós, M., Rodríguez, M., Agullo, J. M., Guardia‐Laguarta, C., Garcı́a-Alloza, M., et al. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.01.019 · Cited by 44
Does low-dose acetylsalicylic acid prevent cognitive decline in women with high cardiovascular risk? A 5-year follow-up of a non-demented population-based cohort of Swedish elderly women
Kern, S., Skoog, I. G., Östling, S., Kern, J., & Börjesson‐Hanson, A. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001288 · Cited by 43
Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer’s Disease
Behl, T., Kaur, I., Frățilă, O., Brata, R. D., & BUNGAU, S. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207443 · Cited by 47
Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer’s disease by meta-analysis and adaptive boosting ensemble learning
Yuen, S. C., Liang, X., Zhu, H., Jia, Y., & Leung, S.-W. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00862-z · Cited by 42
Roles of microglia in Alzheimer’s disease and impact of new findings on microglial heterogeneity as a target for therapeutic intervention
Takata, K., Ginhoux, F., & Shimohama, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114754 · Cited by 40
Adenosine receptor signalling in Alzheimer’s disease
Trinh, P. N. H., Baltos, J., Hellyer, S. D., May, L. T., & Gregory, K. J. (2022) · Purinergic Signalling · doi:10.1007/s11302-022-09883-1 · Cited by 43
Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study
McDowell, B., Marr, C., Holmes, C., Edwards, C. J., Cardwell, C. R., McHenry, M., Meenagh, G., & McGuinness, B. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04417-w · Cited by 39
Sulfhydryl-mediated redox signaling in inflammation: role in neurodegenerative diseases
Miller, O. G., & Mieyal, J. J. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1496-7 · Cited by 40
Immunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?
St‐Amour, I., Cicchetti, F., & Calon, F. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1518-9 · Cited by 40
The role of cofilin in age-related neuroinflammation
Alsegiani, A. S., & Shah, Z. A. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.274330 · Cited by 40
Prostaglandin E2 Receptor Subtype 2 Regulation of Scavenger Receptor CD36 Modulates Microglial Aβ42 Phagocytosis
Li, X., Melief, E. J., Postupna, N. O., Montine, K. S., Keene, C. D., & Montine, T. J. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.09.016 · Cited by 37
ATP-sensitive Potassium Channel Subunits in Neuroinflammation: Novel Drug Targets in Neurodegenerative Disorders
Maqoud, F., Scala, R., Hoxha, M., Zappacosta, B., & Tricarico, D. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210119095626 · Cited by 39
Rheumatoid Arthritis Was Negatively Associated with Alzheimer’s Disease: A Population-Based Case-Control Study
Kao, L., Kang, J., Lin, H., Huang, C., Lee, H., & Chung, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168106 · Cited by 36
Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease
Cimino, P. J., Yang, Y., Li, X., Hemingway, J. F., Cherne, M. K., Khademi, S. B., Fukui, Y., Montine, K. S., Montine, T. J., & Keene, C. D. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.01.002 · Cited by 36
Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology
Beeri, M. S., Schmeidler, J., Lesser, G. T., Maroukian, M., West, R. K., Leung, S., Wysocki, M., Perl, D. P., Purohit, D. P., & Haroutunian, V. H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.011 · Cited by 36
Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases
Desforges, N. M., Hebron, M. L., Algarzae, N. K., Lonskaya, I., & Moussa, C. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/345472 · Cited by 36
The contributions of unscheduled neuronal cell cycle events to the death of neurons in Alzheimer's disease
Herrup, K. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/527 · Cited by 35

Authors: ADAPT Research Group*
Affiliations: Johns Hopkins University (US)
Corresponding author: ADAPT Research Group*
Venue: Archives of Neurology
Publisher: American Medical Association (AMA)
Published: 2008-07-01
Volume: 65
Issue: 7
Pages: 896
ISSN: 0003-9942 (ISSN-L)
DOI: 10.1001/archneur.2008.65.7.nct70006
PMC: PMC2925195
OpenAlex: W1607135210
Cited by: 387
References: 20
Citations by year: 2026: 10 · 2025: 14 · 2024: 9 · 2023: 8 · 2022: 19 · 2021: 15 · 2020: 18 · 2019: 15 · 2018: 9 · 2017: 18 · 2016: 24 · 2015: 25 · 2014: 29 · 2013: 18 · 2012: 34
FWCI: 28.27
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Archives of Neurology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Abbott Laboratories
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
GlaxoSmithKline
Sanofi
Eisai
National Institute on Aging (U01AG015477, U01-AG15477)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords: Alzheimer's disease, cognitive function, naproxen, celecoxib, nonsteroidal anti-inflammatory drugs, chemoprevention, dementia prevention, older adults, cognitive decline, ADAPT trial
MeSH terms: Celecoxib, Aged, Aged, 80 and over, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Cognition, Cognition Disorders, Double-Blind Method, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Naproxen, Pyrazoles, Sulfonamides, Time Factors, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks